7 peptides under active FDA review PCAC MEETING IN 15 DAYS
FindLegitPeptides status board · v2.5.1
Thymosin Beta-4 (full-length)
Tβ4, Tb4, RGN-259 (ophthalmic formulation)
Not 503A eligible

No. Not currently eligible for pharmacy compounding.

Talk to a licensed clinician before acting on this.

Biologic (BLA pathway), not 503A-eligible

Recovery
Sources: prnewswire.com · FDA · ophthalmologytimes.com · newtropin.com

Same category

Related peptides

BPC-157Under PCAC reviewKPVUnder PCAC reviewTB-500Under PCAC reviewCathelicidin LL-37Removed from Cat 2

Before you spend a dollar: confirm the pharmacy is real, and know what a fair price looks like.

Verify a pharmacy See fair pricing